HealthDay News

GU Oncology Now

For patients with prostate cancer, gallium 68 (68Ga)-prostate specific membrane antigen (PSMA)-11 positron emission tomography/computed tomography (PET/CT) has higher sensitivity and specificity for detecting bone metastases than technetium 99m-methyl diphosphonate (99mTc-MDP) bone scintigraphy (BS), according to a meta-analysis published online April 20 in the&nbsp;American Journal of Roentgenology.Gege Zhao, M.D., and Bin Ji, M.D., from the China-Japan Union Hospital of Jilin University in Changchun, China, compared the diagnostic performance of&nbsp;68Ga-PSMA-11 PET/CT to that of&nbsp;99mTc-MDP BS for the detection of bone metastases in patients with prostate cancer in a systematic review. Six studies were included with 546 patients.The researchers found that the pooled sensitivity and specificity were 98 and 97 percent versus 83 and 68 percent for&nbsp;68Ga-PSMA-11 PET/CT versus&nbsp;99mTc-MDP BS, with areas under the receiver operating characteristic curve of 0.99 and 0.85, respectively. In an analysis of five of the studies with 408 patients,&nbsp;68Ga-PSMA-11 PET/CT correctly identified bone metastases in 22.3 percent of the patients who had a negative&nbsp;99mTc-MDP BS result, while bone metastases were correctly identified by&nbsp;99mTc-MDP BS in only 1.9 percent of 210 patients with negative&nbsp;68Ga-PSMA-11 PET/CT.&ldquo;Given the findings, in patients with prostate cancer who have undergone&nbsp;68Ga-PSMA-11 PET/CT,&nbsp;99mTc-MDP BS is highly unlikely to be additive in identifying bone metastases,&rdquo; the authors write.Source: HealthDay News

⁶⁸Ga-PSMA-11 PET/CT Superior to ⁹⁹ᵐTc-MDP BS for ID'ing Bone Metastases

Radioligand therapy prostate-specific membrane antigen

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe